Rethinking DTC Under Scrutiny Eleven months ago, an FDA warning letter was a rare event. Enforcement letters had fallen from more than 130 a year in the late 1990s to just five in all of 2024. Then came last September, when the FDA’s Office of Prescription Drug Promotion (OPDP) sent more than 60 warning and untitled letters in a […] Written by Snow Staff September 1, 2026September 1, 2026
Read this Before You Automate Patient Content Written by Oliver Portmann December 1, 2025May 12, 2026
The End of DTC? Time to Rethink Patient Engagement Written by Snow Staff November 11, 2025November 11, 2025
From Outreach to Ownership: Why Co-Creation Can’t Wait Written by Snow Staff September 25, 2025October 23, 2025
